GMT — Genomtec SA Income Statement
0.000.00%
- PLN111.50m
- PLN107.96m
- PLN0.00m
Annual income statement for Genomtec SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | PRESS | ARS | ARS |
Standards: | PAS | IFRS | — | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.153 | 0.02 | 0.219 | 0.04 | 0.001 |
Cost of Revenue | |||||
Gross Profit | -0.122 | -3.51 | -0.455 | -3.23 | -0.793 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.71 | 10.9 | 5.86 | 11.5 | 8.73 |
Operating Profit | -1.56 | -10.9 | -5.64 | -11.5 | -8.73 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.57 | -10.9 | -5.75 | -11.9 | -9.03 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.45 | -10.9 | -5.27 | -11.9 | -9.01 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.45 | -10.9 | -5.27 | -11.9 | -9.01 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.45 | -10.9 | -5.27 | -11.9 | -9.01 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.177 | -1.34 | -0.646 | -1.27 | -0.735 |
Dividends per Share |